Efavirenz limits HIV infection by :
**Core Concept**
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV infection. It targets the HIV reverse transcriptase enzyme, which is essential for viral replication.
**Why the Correct Answer is Right**
Efavirenz binds to the reverse transcriptase enzyme and induces a conformational change, leading to a decrease in the enzyme's activity. This prevents the viral RNA from being converted into DNA, thereby limiting the replication of the virus. Efavirenz is highly effective in combination with other antiretroviral agents for the treatment of HIV infection.
**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because Efavirenz does not act by inhibiting the protease enzyme, which is a different target for HIV replication.
**Option B:** Incorrect because Efavirenz is not a nucleoside reverse transcriptase inhibitor (NRTI), which is a different class of antiretroviral agents.
**Option C:** Incorrect because Efavirenz does not act by enhancing the immune system's response to HIV, but rather by directly inhibiting viral replication.
**Clinical Pearl / High-Yield Fact**
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) like Efavirenz are often associated with central nervous system (CNS) side effects, such as dizziness and insomnia, due to their ability to cross the blood-brain barrier.
**Correct Answer: C. Non-nucleoside reverse transcriptase inhibition limits HIV replication.**